Amgen

Open: 267.67 Close: 267.7 Change: 0.03

Don't invest in Amgen Company Inc before reading this automated analysis produce by an AI.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, launch, network, academic, partner, choice, lead, and the most common words in the summary are: amgen, job, stock, best, market, news, inc, . One of the sentences in the summary was: Amgen hosted inaugural scientific summit at its headquarters in June, bringing together Amgen Partners.. …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen is best known for it its rheumatoid arthritis drug Enbrel, which contributed 17% of sales last year. Amgen hosted inaugural scientific summit at its headquarters in June, bringing together Amgen Partners.

Today's News

Amgen inc. stock outperforms competitors despite losses on the day - marketwatch.com. Companies such as Amgen (AMGN.O) are training AI to scan billions of public health records, prescription data, medical insurance claims and their internal data. Amgen launches partners of choice network of eight leading oncology academic centers. Amgen is best known for it its rheumatoid arthritis drug Enbrel, which contributed 17% of sales last year. Amgen hosted the inaugural scientific summit at its headquarters in June, bringing together Amgen Partners of Choice members for the official launch of the new academic network. QA Specialist- Qualification and Validation (NPI) Amgen New Albany, OH 2 days ago Be among the first 25 applicants. Since 1991, the Amgen Foundation has given more than $425 million to a wide array of nonprofits. Livingston Memorial was founded in 1947 when Oliva Hathaway, a nurse, made a house call to a patient in Ventura County. At Amgen, our shared mission-to serve patients-drives all that we. At Amgen, our shared mission-to serve patients-drives all that we do. If you feel like youre part of something bigger, its because you are. It is key to our becomi. Amgen launches partners of choice network of eight leading oncology academic centers. Amgen is currently sporting a Zacks Rank of #3 (Hold) Investors should also note Amgens current valuation metrics. Amgen closed the most recent trading day at $269.41, moving -0.76% from the previous trading session. Amgen will be looking to display strength as it nears its next earnings release. The Amgen Tour of California bike race has announced the route of this years route. Amgen launches partners of choice network of eight leading oncology academic centers. Network fosters academic collaboration to advance new treatment options for patients with the greatest unmet needs. Amgen hosted inaugural scientific summit at its headquarters in June. Amgen markets apremilast, a phosphodiesterase-4 (“PDE4”) inhibitor, which is used for treating psoriasis and related conditions, under the brand name Otezla. Amgen launches partners of choice network of eight leading academic centers. Amgen launches partners of choice network of eight leading oncology-academic-centers. Amgen Safety Net Foundation does not charge patients a fee for its assistance. Amgen stock has received a consensus rating of hold. The 64 analysts offering price forecasts for Amgen have a median target of 251.88, with a high estimate of 320.00 and a low estimate of 182.00. Amgen is 90.27% away from the 52-week high.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, launch, network, academic, partner, choice, lead, and the most common words in the summary are: amgen, job, stock, best, market, news, inc, . One of the sentences in the summary was: Amgen hosted inaugural scientific summit at its headquarters in June, bringing together Amgen Partners.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #job #stock #best #market #news #inc.